Immunic director Duane Nash resigns from board
Immunic, Inc. announced the resignation of director Dr. Duane Nash and reduced its board size from ten to nine members.
Rhea-AI Filing Summary
IMMUNIC, INC. (IMUX) reported that on September 10, 2026, Dr. Duane Nash resigned as a member of its Board of Directors. The company stated that Dr. Nash’s resignation was not due to any disagreement regarding its operations, policies, or practices. Following his resignation, the Board, by resolution, reduced its size from ten members to nine members.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Resignation date: September 10, 2026
Board size before change: 10 members
Board size after change: 9 members
+1 more
4 metrics
Resignation date
September 10, 2026
Date on which Dr. Duane Nash resigned from the Board of Directors
Board size before change
10 members
Size of the Board of Directors prior to the resolution following Dr. Nash’s resignation
Board size after change
9 members
Size of the Board of Directors after the Board adopted a resolution in connection with the resignation
Exhibit 104
1 exhibit
Cover Page Interactive Data File with Inline XBRL cover page tags
Key Terms
Board of Directors, Inline XBRL, Cover Page Interactive Data File, Emerging growth company
4 terms
Board of Directors regulatory
"resigned as a member of the Board of Directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Inline XBRL technical
"XBRL tags are embedded within the Inline XBRL document"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Cover Page Interactive Data File technical
"Cover Page Interactive Data File-the cover page XBRL tags"
Emerging growth company regulatory
"Emerging growth company Yes No"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did IMMUNIC, INC. (IMUX) disclose on September 10, 2026?
IMMUNIC, INC. disclosed that on September 10, 2026, Dr. Duane Nash resigned as a member of its Board of Directors, and the Board adopted a resolution reducing its size from ten members to nine members.
Did Dr. Duane Nash resign from IMUX due to a disagreement with the company?
No. The company stated that Dr. Duane Nash’s resignation was not the result of any disagreement with Immunic, Inc. on any matter relating to its operations, policies, or practices.
How did Immunic, Inc. (IMUX) change the size of its Board after the resignation?
In connection with Dr. Nash’s resignation, Immunic, Inc. reported that its Board of Directors passed a resolution to reduce the Board’s size from ten members to nine members.
What role does Erik Lundgren hold at IMMUNIC, INC. (IMUX)?
Erik Lundgren is the Chief Executive Officer of Immunic, Inc. He signed the Form 8-K on behalf of the company as its duly authorized officer on September 11, 2026.
What exhibit was included with this Immunic, Inc. (IMUX) Form 8-K?
The filing lists Exhibit 104, described as the Cover Page Interactive Data File, indicating that the cover page XBRL tags are embedded within the Inline XBRL document.
AI-generated analysis. How Rhea-AI works. Not financial advice.
